Targeted therapies against receptor tyrosine kinases (RTKs) are currently used with success in cancers displaying clear oncogene addiction, such as in epidermal growth factor receptor (EGFR)‐mutated lung cancers [1]. This evidence concerns the gene EGFR and lung carcinoma.